WO2023163318A1 - Produit de fermentation contenant un acide gras à chaîne courte et son utilisation pour soulager, prévenir et traiter l'obésité - Google Patents

Produit de fermentation contenant un acide gras à chaîne courte et son utilisation pour soulager, prévenir et traiter l'obésité Download PDF

Info

Publication number
WO2023163318A1
WO2023163318A1 PCT/KR2022/017492 KR2022017492W WO2023163318A1 WO 2023163318 A1 WO2023163318 A1 WO 2023163318A1 KR 2022017492 W KR2022017492 W KR 2022017492W WO 2023163318 A1 WO2023163318 A1 WO 2023163318A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
fermentation product
medium composition
composition
medium
Prior art date
Application number
PCT/KR2022/017492
Other languages
English (en)
Korean (ko)
Inventor
김유미
장기현
석창환
신지원
곽윤금상
Original Assignee
(주) 바이노텍
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주) 바이노텍 filed Critical (주) 바이노텍
Priority claimed from KR1020220148277A external-priority patent/KR102660139B1/ko
Publication of WO2023163318A1 publication Critical patent/WO2023163318A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/52—Propionic acid; Butyric acids

Definitions

  • the present invention relates to the use of a fermentation product containing short-chain fatty acids for the improvement, prevention or treatment of overweight.
  • Garcinia cambogia In relation to weight loss, Garcinia cambogia, green tea extract, conjugated linolenic acid, and the like are used as body fat reduction supplements or functional food materials. Garcinia cambogia accounts for about 47% of the body fat reduction market by suppressing fat absorption, but side effects such as liver toxicity are appearing.
  • microorganisms live in symbiosis with the human body, performing various functions related to metabolic function control, immune system development, interaction with the nervous system, and maintenance of homeostasis of the human body, such as human digestive function or securing energy.
  • microorganisms living in the intestine can have a great impact on human health, including not only intestinal diseases, but also metabolic diseases such as obesity and diabetes, mental diseases such as depression and ADHD, and aging.
  • Short-chain fatty acids refer to organic acids having 6 carbon atoms or less, such as acetate, propionate, and butyrate. These short-chain fatty acids can have a lot of effects on our body. For example, cells constituting the mucous membrane of the large intestine maintain the wall of the large intestine using short-chain fatty acids as an energy source and can prevent bacteria from entering the body.
  • butyrate is absorbed into the colonic mucosa and plays an important role in proliferating mucosal epithelial cells of all digestive tracts and organs.
  • Butyrate activates the FFAR3 (Free Fatty Acid Receptor 3) cell membrane receptor in fat cells (PPAR- ⁇ correction or not), which prevents the accumulation of fat and uses energy for muscle and metabolism, which is very effective for weight loss and diet. Results have been disclosed.
  • Hua. V. In an animal model of obese mice by Lin et al, it was reported that when a high-fat diet containing butyrate was administered for 4 weeks, a significant reduction in body fat was reported (Hua V. Lin et al., PLoS One. 2012 ;7(4): e35240).
  • butyrate shows many clinical effects in reducing body fat, it has a very strong specific odor and is difficult to commercialize.
  • butyrate-producing microorganisms in the intestine produce butyrate in the process of decomposing resistant starch such as inulin, which is a water-soluble dietary fiber.
  • the present invention is intended to provide a fermentation product with a high content of short-chain fatty acids.
  • the present invention also aims to improve, prevent or treat overweight by using the fermentation product.
  • the present invention also seeks to provide a method for preparing the fermentation product.
  • the term "about” means within 10%, preferably within 5%, more preferably within 1% of a given value or range.
  • the present invention provides a fermentation product comprising a high concentration of short chain fatty acids.
  • the fermentation product is produced by inoculating a Clostridium strain into a medium composition and then fermenting it, in which case it contains a high concentration of short-chain fatty acids.
  • the present invention is a fermentation product comprising short-chain fatty acids
  • the fermentation product is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • yeast extract as a nitrogen source; and at least one of roasted soy flour or soy peptone;
  • the fermentation product comprises at least about 10 mM short-chain fatty acids.
  • a fermentation product comprising short chain fatty acids is provided.
  • the term "fermentation product” refers to a product of enzymatic or metabolic decomposition using microorganisms, and specifically, in the present invention, Clostridium (Clostridium ) may refer to a product cultured after inoculation of a strain.
  • “fermentation product” herein may be used interchangeably with “fermentation product” and the like.
  • the term “medium” or “medium composition” refers to a material in which nutrients necessary for culturing the microorganism or strain are mixed as main components, including water essential for survival and growth, as well as nutrients and growth supplies, etc.
  • the medium composition of the present application includes a composition and content optimal for producing short-chain fatty acids, particularly butyrate in high concentration, as a nitrogen source; and at least one of roasted soy flour or soy peptone; and at least one selected from the group consisting of inulin, chicory powder, maltodextrin and glucose as a carbon source as an essential component.
  • growth factors such as inorganic salts, amino acids and/or vitamins may be additionally included.
  • the medium composition of the present invention can be cultured while controlling temperature, pH, etc. under anaerobic conditions in a conventional medium.
  • Yeast extract, roasted soy flour, soy peptone, etc. included in the medium composition function as a nitrogen source, and the composition of the nitrogen source may be very important in the growth of microorganisms.
  • the medium composition includes the yeast extract and additionally includes at least one of roasted soybean flour or soy peptone, the amount of butyrate produced can be increased, and thus the improvement, prevention, or treatment effect of butyrate on overweight can be improved.
  • the nitrogen source may essentially include yeast extract and roasted soybean flour, or may essentially include yeast extract and soy peptone.
  • the yeast extract may be included in about 0.1 to 10% by weight, preferably about 0.5 to 5% by weight, more preferably about 0.5 to 1% by weight, such as about 0.5 or 1% by weight, based on the total weight of the medium composition. may be %.
  • Yeast extracts commercially available may be appropriately used, for example, those containing protein or amino acid components as a nitrogen source or may be purchased as Powdered Yeast Extract-II from Choheung Co., Ltd.
  • Roasted soybean flour may be included in about 0.1 to 10% by weight, preferably about 0.5 to 7% by weight, more preferably about 2 to 6% by weight, more preferably about 0.1 to 10% by weight based on the total weight of the medium composition. 1 to 5 weight percent, such as about 1, 3, or 5 weight percent.
  • Roasted soybean flour can be suitably used commercially available, for example, commercially available ones containing protein or amino acid components as a nitrogen source can be appropriately purchased and used (for example, available from Ilho Foods).
  • Soy peptone may be included in about 0.1 to 10% by weight, preferably about 0.5 to 7% by weight, more preferably about 2 to 6% by weight, more preferably about 0.1 to 10% by weight based on the total weight of the medium composition. 1 to 5% by weight, such as about 5% by weight. Soy peptone can be suitably used commercially available, and can be purchased from SOLABIA, for example.
  • the medium composition may further include skim milk powder as a nitrogen source.
  • Skim milk powder may be included in about 0.1 to 10% by weight, preferably about 0.5 to 7% by weight, more preferably about 2 to 6% by weight, more preferably about 0.1 to 10% by weight based on the total weight of the medium composition. 1 to 5% by weight, such as about 5% by weight. Skim milk powder commercially available can be suitably used, and can be purchased from Seoul Milk, for example.
  • the medium composition includes a carbon source as an essential component in addition to a nitrogen source, and the carbon source is at least one selected from the group consisting of inulin, chicory powder, maltodextrin, and glucose.
  • the carbon source may be included in about 1 to 40% by weight, preferably about 5 to 20% by weight, such as about 5, 10, and 13% by weight, based on the weight of the total medium composition.
  • the carbon source comprises alone one of inulin, chicory powder, maltodextrin and glucose, or consists essentially of inulin and chicory powder, or consists essentially of inulin, chicory powder and maltodextrin. can be included as
  • Each carbon source can affect the amount of butyrate produced.
  • inulin may be included in about 1 to 10% by weight, and within this range, the amount of butyrate produced may further increase. More preferably, it may be about 3 to 7% by weight, such as about 5% by weight.
  • Inulin commercially available commercially available products may be suitably used, and may be obtained from, for example, BIOGLAN.
  • Chicory powder may be included in about 1 to 10% by weight, preferably about 3 to 7% by weight, such as about 5% by weight, based on the weight of the total medium composition.
  • Chicory powder can be suitably used commercially available commercially, for example, it can be purchased from Joeun Herbs.
  • Maltodextrin may be included in about 1 to 10% by weight, preferably about 3 to 7% by weight, such as about 3 or 5% by weight, based on the weight of the total medium composition.
  • the maltodextrin may be, for example, indigestible maltodextrin.
  • Commercially available maltodextrins may be appropriately used, and may be purchased from Samyang Corporation, for example.
  • Glucose may be included in about 1 to 10% by weight, preferably about 3 to 7% by weight, such as about 5% by weight, based on the weight of the total medium composition. Glucose commercially available may be appropriately used, and may be purchased from Samyang Corporation, for example.
  • the medium composition consists of guar gum, sodium alginate, pectin and oligosaccharides (e.g., galactooligosaccharide, fructooligosaccharide, isomaltooligosaccharide, xylooligosaccharide, soybean oligosaccharide, lactulose, chitin oligosaccharide, isomaltooligosaccharide, etc.) as a carbon source. It may further include one or more selected from the group.
  • oligosaccharides e.g., galactooligosaccharide, fructooligosaccharide, isomaltooligosaccharide, xylooligosaccharide, soybean oligosaccharide, lactulose, chitin oligosaccharide, isomaltooligosaccharide, etc.
  • the guar gum may be included in about 0.1 to 5% by weight, preferably about 0.1 to 1% by weight, for example, about 0.3% by weight based on the weight of the total medium composition.
  • the sodium alginate may be included in about 0.1 to 5% by weight, preferably about 0.1 to 1% by weight, for example, about 0.3% by weight based on the weight of the total medium composition.
  • the pectin may be included in about 0.1 to 5% by weight, preferably about 0.1 to 1% by weight, for example, about 0.3% by weight based on the weight of the total medium composition.
  • the oligosaccharide eg, galactooligosaccharide, fructooligosaccharide, isomaltooligosaccharide, xylooligosaccharide, soybean oligosaccharide, lactulose, chitin oligosaccharide, isomaltooligosaccharide, etc.
  • the oligosaccharide is about 0.1 to 5 weight based on the weight of the total medium composition. %, preferably about 1 to 3% by weight, such as about 3% by weight.
  • the medium composition may further include one or more inorganic salts selected from the group consisting of sodium chloride, sodium dehydroacetate, dibasic potassium phosphate, magnesium sulfate, ammonium sulfate and calcium carbonate.
  • Each of the inorganic salts is about 0.01 to 5% by weight, preferably about 0.05 to 1% by weight, such as about 0.06% by weight, about 0.1% by weight, about 0.3% by weight, about 0.4% by weight, based on the weight of the total medium composition. %, about 0.5% by weight, or about 1% by weight.
  • the medium composition contains about 0.5% by weight of sodium chloride, about 0.3% by weight of sodium dehydroacetate, about 0.3% by weight of dibasic potassium phosphate, about 0.06% by weight of magnesium sulfate, about 0.4% by weight of ammonium sulfate and 1 calcium carbonate. Further includes % by weight.
  • the medium composition includes the above-mentioned nitrogen source and carbon source, and optionally the above-mentioned inorganic salts, the production of butyrate is increased, so that the effect of preventing overweight of the fermentation product may be further improved.
  • the medium composition based on the total weight of the medium composition, 0.1 to 10% by weight of yeast extract as a nitrogen source; and 0.1 to 10% by weight of roasted soybean flour or 0.1 to 10% by weight of soy peptone; and
  • At least one selected from the group consisting of 1 to 10% by weight of inulin, 1 to 10% by weight of chicory powder, 1 to 10% by weight of maltodextrin, and 1 to 10% by weight of glucose may be included.
  • the medium composition may further include 0.1 to 10% by weight of skim milk powder as a nitrogen source based on the total weight of the medium composition.
  • the medium composition may further include at least one selected from the group consisting of 0.1 to 5% by weight of guar gum, 0.1 to 5% by weight of sodium alginate, 0.1 to 5% by weight of pectin, and 0.1 to 5% by weight of oligosaccharide as a carbon source. there is.
  • the medium composition based on the total weight of the medium composition,
  • yeast extract as a nitrogen source
  • roasted soybean flour or 5% by weight of soy peptone
  • the medium composition may further include 5% by weight of skim milk powder as a nitrogen source based on the total weight of the medium composition.
  • the medium composition based on the total weight of the medium composition, at least one selected from the group consisting of 0.3% by weight of guar gum, 0.3% by weight of sodium alginate, 0.3% by weight of pectin, and 3% by weight of oligosaccharide as a carbon source Further can include
  • the medium composition also contains 0.5% by weight of sodium chloride, 0.3% by weight of sodium dehydroacetate, 0.3% by weight of potassium dihydrogen phosphate, 0.06% by weight of magnesium sulfate, 0.4% by weight of ammonium sulfate and carbonic acid, based on the total weight of the medium composition.
  • Calcium 1% by weight of inorganic salts may be further included.
  • the medium composition may have the composition of Examples 1 to 17 mentioned in Tables 1 and 2.
  • the improvement effect of the composition on overweight can be further improved.
  • the productivity of butyrate may be lowered, and the culture medium composition may not be dissolved well, precipitate may occur, or boiling may occur during sterilization.
  • the medium composition based on the total weight of the medium composition, yeast extract as a nitrogen source 0.5% by weight; And 5% by weight of soy peptone,
  • the medium composition When inorganic salts of 0.5% by weight of sodium chloride, 0.3% by weight of sodium dehydroacetate, 0.3% by weight of potassium dibasic phosphate, 0.06% by weight of magnesium sulfate, 0.4% by weight of ammonium sulfate, and 1% by weight of calcium carbonate are included, the medium composition
  • the solubility may be improved and the amount of butyrate produced may increase to about 90 mM or more, preferably about 100 mM or more, and more preferably about 200 mM or more.
  • the short chain fatty acid is butyrate, propionate, acetate, specifically butyrate.
  • the fermentation product of the present invention contains at least about 10 mM butyrate, such as at least about 20 mM, or at least about 30 mM, at least about 40 mM, at least about 50 mM, at least about 60 mM, at least about 70 mM, at least about 80 mM.
  • about 90 mM or more about 100 mM or more, about 110 mM or more, about 120 mM or more, about 130 mM or more, about 140 mM or more, about 150 mM or more, about 160 mM or more, about 170 mM or more, about 180 mM or more , It may include about 190 mM or more, about 200 mM or more, about 210 mM or more butyrate.
  • a composition containing short-chain fatty acids can be prepared by inoculating a Clostridium strain into the aforementioned medium composition and then fermenting (cultivating) the strain. This production method and culture conditions are described later.
  • the medium composition of the present invention does not contain RCM (Reinforced Clostridial Medium).
  • RCM is a medium used for culturing Clostridium and other anaerobic bacteria in the food and medical fields. This medium is used as an enrichment medium for microbiological testing of non-sterilized products, and is also a standard medium registered in USP, EP, and JP.
  • the medium includes Beef extract, Casein peptone, Dextrose, Sodium chloride, Sodium acetate, Yeast extract, Soluble Starch, L-Cysteine HCl, Agar, and the like, and is easily commercially available.
  • RCM is also used as a differential medium for sulfite reducing bacteria such as Clostridium perfringens in food and beverage fields. Since the use and purpose of RCM is difficult to use in food production as a reagent prepared for experiments, it is necessary not to use RCM in order to prepare commercial food compositions and the like.
  • the Clostridium strain is one of Clostridium butyricum, Clostridium tyrobutyricum, or Clostridium saccharoperbutylacetonicum. It includes the above, and specifically, it is Clostridium butyricum.
  • the present invention provides a yeast extract as a nitrogen source; and at least one of roasted soy flour or soy peptone; and at least one selected from the group consisting of inulin, chicory powder, maltodextrin, and glucose as a carbon source, and does not include an enriched Clostridia medium.
  • the medium composition can be used as a medium for producing short-chain fatty acids.
  • the medium composition may further include skim milk powder as a nitrogen source.
  • the medium composition may further include at least one selected from the group consisting of guar gum, sodium alginate, pectin, and oligosaccharides as a carbon source.
  • the medium composition may further include inorganic salts, for example, one or more inorganic salts selected from the group consisting of sodium chloride, sodium dehydroacetate, dibasic potassium phosphate, magnesium sulfate, ammonium sulfate and calcium carbonate.
  • inorganic salts for example, one or more inorganic salts selected from the group consisting of sodium chloride, sodium dehydroacetate, dibasic potassium phosphate, magnesium sulfate, ammonium sulfate and calcium carbonate.
  • the fermentation product of the present invention can be used for the amelioration, prevention or treatment of overweight.
  • the fermented composition of the present invention exhibits an effect of inhibiting differentiation of adipocytes, reducing fat accumulation, and further inhibiting triglyceride content.
  • the fermentation product of the present invention showed an effect of significantly reducing body weight in the high-fat diet group, and also reduced the percentage of body fat and the amount of body fat.
  • the fermented composition of the present invention can suppress the expression of mast cells and reduce body weight and fat mass, so that it can be used for improvement, prevention or treatment of overweight.
  • the fermentation product of the present invention also exhibits a concentration-dependent antioxidant effect, and furthermore, it has been confirmed that it reduces the level of TNF alpha, showing an effect on improving inflammatory diseases.
  • the present invention provides a composition comprising the fermentation product.
  • the composition may be used for improvement, prevention or treatment of overweight.
  • the present invention provides a pharmaceutical composition or veterinary composition for preventing or treating overweight, comprising the fermentation product.
  • the present invention provides a food composition or animal feed composition for improving or preventing overweight, comprising the fermentation product.
  • composition includes a product comprising a specified component in a specified amount and any product that results directly or indirectly from the combination of a specified component in a specified amount.
  • this term encompasses a product comprising an active ingredient and an inactive ingredient constituting a carrier, and includes any combination, complexation or aggregation of two or more ingredients or dissociation of one or more ingredients, or other types of It is intended to include any product resulting directly or indirectly by a reaction or interaction.
  • composition refers to a pharmaceutical composition for use as a medicine for humans, a veterinary composition for use as a medicine for animals, or a dietary product or food for humans or animals (e.g., functional food composition, health functional food, i.e., food, beverage, feed or pet food, or food, beverage, animal feed or pet food supplement); Accordingly, “composition” herein is used as a meaning including both “pharmaceutical composition", “veterinary composition", or “food composition”.
  • the composition may further include a pharmaceutically acceptable excipient, a veterinarily acceptable excipient, a food acceptable excipient, and the like, depending on each use.
  • phrases “pharmaceutically acceptable,” “veterinarily acceptable,” or “food acceptable” means, within the scope of sound medical or food judgment, to match a reasonable benefit/risk ratio, excessive toxicity, Refers to a compound, material, composition, carrier, and/or dosage form suitable for use in contact with human or animal tissue without irritation, allergic reaction, or other problem or complication.
  • phrases “pharmaceutically acceptable excipient”, “veterinarily acceptable excipient” or “food acceptable excipient” are generally safe, non-toxic, biologically and otherwise desirable pharmaceutical, veterinary or otherwise acceptable excipients. It means an excipient useful for preparing a food composition, and includes an excipient acceptable for human pharmaceutical use or animal veterinary use, and further for food use. As used in the specification and claims, “pharmaceutically acceptable excipient”, “veterinarily acceptable excipient”, or “food acceptable ingredient” includes both one or more of these excipients.
  • pharmaceutically, veterinarily, or food-acceptable excipients used in the formulation of the present invention may be diluents or inert carriers, lubricants, binders, or combinations thereof. Excipients used in the formulations of the present invention may further include fillers, anti-microbial agents, antioxidants, anti-caking agents, coating agents, or mixtures thereof. Any other pharmaceutical, veterinary, or food acceptable excipient may be used without limitation.
  • the composition according to the present invention may be a pharmaceutical or veterinary composition for improving, preventing or treating overweight, a food composition for improving overweight, and may be used for various other purposes.
  • the composition of the present invention may be used for anti-inflammatory or antioxidant purposes in addition to overweight improvement.
  • composition according to the present invention can be administered to the human body in a variety of ways, and can also be administered to other mammals.
  • other mammals may be domestic animals such as dogs, cats, rabbits, pigs, sheep, goats, dairy cows, horses, and cattle, and pets, but are not limited thereto.
  • the composition when the composition is a pharmaceutical or veterinary composition, the composition may be formulated into a variety of forms for parenteral or oral administration.
  • Representative formulations for parenteral administration include formulations for injection, and in this case, the form of the composition may be preferably an isotonic aqueous solution or suspension.
  • Formulations for injection may be prepared according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. For example, each component may be dissolved in saline or a buffer solution and formulated for injection.
  • Formulations for oral use may include powders, granules, tablets, pills, capsules, and the like, but are not limited thereto.
  • composition according to the present invention can be prepared in various formulations using a drug delivery system.
  • the drug delivery system may be liposomes, ethosomes, elastic ethosomes, targeting liposomes, microparticles, microcapsules, nanoparticles, nanocapsules, nanofibers, and the like, but is not limited thereto.
  • compositions for food include, for example, health functional foods, vitamin complexes, chewing gum, beverages, various foods, tea, various processed meat products, fish products, tofu, jelly, noodles, breads, health supplements, seasonings, sauces, confectionery, Candies, dairy products, other processed foods, fermented foods, natural seasonings, etc. can be used, but are not limited thereto.
  • the term "health functional food” refers to food manufactured and processed using raw materials or ingredients having useful functionality for the human body.
  • the above “functionality” means obtaining useful effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological functions.
  • the health functional food of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and components commonly added in the art during manufacture.
  • the formulation of the health functional food may also be manufactured without limitation as long as the formulation is recognized as a health functional food.
  • yeast extract as a nitrogen source; and at least one of roasted soy flour or soy peptone;
  • Preparing a medium composition by dissolving and sterilizing at least one selected from the group consisting of inulin, chicory powder, maltodextrin and glucose as a carbon source in water;
  • Sterilization in step (a) may be performed by heating at a temperature of about 100 to 130° C. for about 10 to 20 minutes, and under these conditions, sterilization can be effectively achieved.
  • the heating temperature may be about 120° C.
  • the heating time may be about 15 minutes.
  • step (c) fermentation can be performed for about 1 to 15 days by putting an anaerobic pack in an anaerobic culture tank to maintain the culture state anaerobically. More preferably, the culture may be performed for about 1 to 5 days. At this time, the culture temperature may be about 25 ⁇ 37 °C. For example, the incubation period may be about 5 days and the incubation temperature may be about 37°C.
  • the fermented composition of the present invention can suppress the expression of mast cells and reduce body weight and fat mass, so that it can be effectively used for improvement, prevention or treatment of overweight.
  • 1 is a graph showing the results of measuring the cytotoxicity of compositions according to Examples in intestinal endothelial cells.
  • Figure 2 is a graph showing the results of measuring the antioxidant efficacy of the composition according to the embodiment.
  • Figure 3 is a graph showing the results of measuring the decrease in TNF alpha level in primary cultured splenocytes for the composition according to the Example.
  • Figure 4 is a graph showing the results of measuring the IgE level reduction in the plasma of animals with DSS-induced enteritis for the composition according to the Example.
  • Figure 5 is a graph showing the results of measuring the cytotoxicity evaluation on 3T3-L1 preadipocyte cells for the composition according to the example.
  • 6 is a graph showing the results of measuring the induction of differentiation from 3T3-L1 preadipocytes to adipocytes with respect to the composition according to the example.
  • Figure 9 is the result of measuring the weight change in obesity-induced mice on a high-fat diet according to the administration of the composition according to the embodiment.
  • a small amount of 1 platinum of Clostridium butyricum cultured on a solid medium is inoculated into a sterilized culture medium, and in order to maintain an anaerobic state in an incubator at 37 ° C, the medium is placed in an anaerobic culture tank 2.5 L, Incubated using a gas pack. Thereafter, the anaerobic culture status indicator paper was used to check the presence or absence of oxygen in the anaerobic culture tank, and the cells were cultured for a total of 5 days.
  • a composition was prepared under the same conditions as in Example 1, except that 3% by weight (based on the total culture medium) of roasted soy flour was added.
  • a composition was prepared under the same conditions as in Example 1, except that 5% by weight of roasted soybean flour (based on the total culture medium) was added.
  • a composition was prepared under the same conditions as in Example 3, except that 0.3% by weight of guar gum (based on the total culture medium) was additionally added.
  • a composition was prepared under the same conditions as in Example 3, except that 0.3% by weight of sodium alginate (based on the total culture medium) was additionally added.
  • a composition was prepared under the same conditions as in Example 3, except that 0.3% by weight (based on the total culture medium) of pectin was additionally added.
  • a composition was prepared under the same conditions as in Example 3, except that 3% by weight (based on the total culture medium) of fructooligosaccharide powder was additionally added.
  • a composition was prepared under the same conditions as in Example 3, except that 3% by weight (based on the total culture medium) of galacto-oligosaccharide was additionally added.
  • a composition was prepared under the same conditions as in Example 3, except that 3% by weight (based on the total culture medium) of indigestible maltodextrin was additionally added.
  • a small amount of 1 platinum of Clostridium butyricum cultured on a solid medium is inoculated into a sterilized culture medium, and in order to maintain an anaerobic state in a 37 ° C incubator, the medium is placed in an anaerobic culture tank 2.5 L, Incubated using a gas pack. Thereafter, the anaerobic culture status indicator paper was used to check the presence or absence of oxygen in the anaerobic culture tank, and the cells were cultured for a total of 5 days.
  • a composition was prepared under the same conditions as in Example 10, except that 5% by weight of chicory powder was added as a carbon source.
  • a composition was prepared under the same conditions as in Example 10, except that 5% by weight of indigestible maltodextrin was added as a carbon source.
  • a composition was prepared under the same conditions as in Example 10, except that 5% by weight of glucose was added as a carbon source.
  • Yeast extract 0.5% by weight as a nitrogen source 0.5% by weight as a nitrogen source; And a composition was prepared under the same conditions as in Example 10, except that 5% by weight of each of soy peptone and skim milk powder was added.
  • Yeast extract 0.5% by weight as a nitrogen source 0.5% by weight as a nitrogen source; And a composition was prepared under the same conditions as in Example 10, except that 5% by weight of each of soy peptone and skim milk powder and 5% by weight of chicory powder as a carbon source were added.
  • Yeast extract 0.5% by weight as a nitrogen source A composition was prepared under the same conditions as in Example 10, except that 5% by weight of each of soy peptone and skim milk powder and 5% by weight of indigestible maltodextrin as a carbon source were added.
  • Yeast extract 0.5% by weight as a nitrogen source A composition was prepared under the same conditions as in Example 10, except that 5% by weight of each of soy peptone and skim milk powder and 5% by weight of glucose as a carbon source were added.
  • RCM Reinforced Clostridial Medium
  • the prepared culture medium a small amount of 1 platinum is collected and inoculated with Clostridium butyricum cultured on RCM solid medium, and in order to maintain an anaerobic state in an incubator at 37 ° C, the medium is placed in a 2.5 L anaerobic culture tank , cultured using a gas pack. Thereafter, the anaerobic culture status indicator paper was used to check the presence or absence of oxygen inside the anaerobic culture tank, and the culture was carried out for a total of 5 days.
  • a composition was prepared under the same conditions as in Comparative Example 1, except that 1% by weight of inulin powder was added based on the total culture medium prior to sterilization.
  • a composition was prepared under the same conditions as in Comparative Example 2, except that 5% by weight of inulin powder was added based on the total culture medium.
  • a composition was prepared under the same conditions as in Comparative Example 2, except that 10% by weight of inulin powder was added based on the total culture medium.
  • a composition was prepared under the same conditions as in Comparative Example 2, except that 20% by weight of inulin powder was added based on the total culture medium.
  • a composition was prepared under the same conditions as in Comparative Example 2, except that 5% by weight of chicory powder was added based on the total culture medium instead of inulin powder.
  • a small amount of 1 platinum of Clostridium butyricum cultured on a solid medium is inoculated into a sterilized culture medium, and in order to maintain an anaerobic state in an incubator at 37 ° C, the medium is placed in an anaerobic culture tank 2.5 L, Incubated using a gas pack. Thereafter, the anaerobic culture status indicator paper was used to check the presence or absence of oxygen in the anaerobic culture tank, and the cells were cultured for a total of 5 days.
  • a composition was prepared under the same conditions as in Comparative Example 7, except that 1% by weight (based on the total culture medium) of whey protein isolate was added instead of soybean protein isolate.
  • a small amount of 1 platinum of Clostridium butyricum cultured on a solid medium is inoculated into a sterilized culture medium, and in order to maintain an anaerobic state in a 37 ° C. incubator, the medium is placed in an anaerobic culture tank 2.5 L, Incubated using a gas pack. Thereafter, the anaerobic culture status indicator paper was used to check the presence or absence of oxygen in the anaerobic culture tank, and the cells were cultured for a total of 5 days.
  • a composition was prepared under the same conditions as in Comparative Example 9, except that 5% by weight of chicory powder was added as a carbon source.
  • a composition was prepared under the same conditions as in Comparative Example 9, except that 5% by weight of indigestible maltodextrin was added as a carbon source.
  • a composition was prepared under the same conditions as in Comparative Example 9, except that 5% by weight of glucose was added as a carbon source.
  • compositions of Examples 1 to 17 and Comparative Examples 1 to 12 are summarized and shown in Tables 1 to 3 below.
  • Examples 1 to 3 include both inulin and chicory powder, and when Examples 1 to 3 are compared with Comparative Examples 7 and 8, there is a difference in including roasted soy flour as a composition of the medium composition.
  • roasted soy flour was produced, especially when the roasted soybean flour was 3% by weight (based on the total medium weight) (Example 2), and when the roasted soybean flour was 5% by weight (based on the total medium weight) (Example 3), It can be seen that the production of butyrate was markedly increased to 21.25 mM and 25.96 mM, respectively.
  • Example 4 to 9 compared to Example 3, which additionally include a carbon source in the medium composition, butyrate production was almost similar to Example 3 or slightly increased.
  • the medium compositions of Examples 10 to 17 include yeast extract and soy peptone as nitrogen sources, inulin, chicory powder, maltodextrin or glucose as carbon sources, sodium chloride, sodium dehydroacetate, dibasic potassium phosphate, magnesium sulfate, It further includes inorganic salts of ammonium sulfate and calcium carbonate.
  • yeast extract and soy peptone as nitrogen sources
  • inulin, chicory powder maltodextrin or glucose as carbon sources
  • sodium chloride sodium dehydroacetate
  • dibasic potassium phosphate sodium dehydroacetate
  • dibasic potassium phosphate dibasic potassium phosphate
  • magnesium sulfate magnesium sulfate
  • the solubility during the preparation of the medium composition was improved, and the amount of butyrate produced increased to 90 mM or more, and in particular, in Examples 10 to 12, it increased to 200 mM or more. did
  • the cell viability of the composition (fermentation product) of Example 3 was measured as a lyophilized sample through the MTT method.
  • IEC-18 cells Intestinal endothelial cells, IEC-18 cells, were cultured in DMEM (Dulbecco's Modified Eagle Medium, Hyclone Lab., USA) containing 10% fetal bovine serum (FBS), and then plated at 5 x 104 cells/cells in a 24 well plate. Divided into mL. After culturing for 48 hours, 100 ⁇ g/mL of LPS and the lyophilized sample were simultaneously treated. At this time, the lyophilized samples were reconstituted in an aqueous medium (water) at 10, 50, 100, 250, 500, and 1000 ug/ml, respectively. After the incubation was completed, the MTT reagent was treated and reacted to form formazan, and the supernatant was removed, treated with DMSO, and measured at 540 nm using a microplate reader ELISA device.
  • DMEM Dulbecco's Modified Eagle Medium, Hyclone Lab., USA
  • FBS feta
  • Example 3 The fermentation product of Example 3 was lyophilized, and antioxidant and anti-inflammatory activities were evaluated.
  • the antioxidant efficacy was verified through the DPPH experiment, and ascorbic acid (1 mg/mL) was used as a control and compared with the fermentation product.
  • the lyophilized samples were reconstituted in an aqueous medium (water) to 1, 2.5, 5, 7.5, and 10 ug/ml, respectively.
  • a 0.2 mM DPPH solution was used, and each sample, purified water, MeOH, and 0,2 mM DPPH were sequentially mixed in a 96 well plate and reacted in the dark for 30 minutes. After that, the optical density (OD) at a wavelength of 517 nm was calculated using a microplate reader ELISA device and compared with that of ascorbic acid (control).
  • a TNF alpha measurement experiment was conducted in spleen cells of a mouse animal model of Dextran Sulfate Sodium (DSS) enteritis.
  • the untreated mice were used as a normal control (CON)
  • the DSS mouse model was used as a negative control (DSS)
  • Butyric acid 5 mM, 10 mM, and Sulfasalazine 50 mg/kg were used as positive controls.
  • the freeze-dried sample was reconstituted at a low concentration of 100 ug/mL and a high concentration of 200 ug/mL in the same manner as in Experimental Example 3 and used.
  • TNF alpha measurement was performed using a TNF alpha Mouse ELISA kit.
  • the sample of the present invention showed a higher reducing ability than Butyric acid, and showed an effect similar to that of Sulfasalazine.
  • TNF alpha is a cytokine that plays an important role in various immune-mediated inflammatory diseases, and the reduced TNF alpha level indicates that the composition of the present invention is effective in improving inflammatory diseases.
  • a freeze-dried sample of the fermentation product of Example 3 was used to measure IgE levels in plasma of mouse animals with DSS-induced enteritis using a Mouse IgE ELISA kit.
  • the sample of Example 3 was reconstituted at a low concentration of 100 ug/mL and a high concentration of 200 ug/mL and used.
  • the butyrate fermentation product showed a concentration-dependent decrease in IgE level, and it was confirmed in FIG. 4 that the IgE level decreased the most at a high concentration (200 ug/mL) of the butyrate fermentation product. This indicates that the composition of the present invention is effective in improving inflammatory diseases.
  • the freeze-dried sample of the fermentation product of Example 3 was reconstituted in an aqueous medium (water) at concentrations of 25, 50, 100, and 200 ⁇ g/ml, respectively, and then treated with 3T3-L1 cells, respectively, followed by the MTT method. Cell viability was measured through The MTT method was performed in the same manner as in Experimental Example 2.
  • the freeze-dried sample of the butyrate fermentation product of Example 3 was reconstituted with an aqueous medium (water) and then treated at concentrations of 25, 50, and 100 ⁇ g/ml to induce differentiation of 3T3-L1 preadipocytes into mature adipocytes and treated with Oil Red-O staining.
  • 3T3-L1 cells, pre-adipocytes were cultured in DMEM (Dulbecco's Modified Eagle Medium, Hyclone Lab., USA) containing 10% Bovine calf serum, and then plated 1 x 10 in a 6-well plate. It was aliquoted at 5 cells/mL.
  • DMEM fetal bovine serum
  • FBS fetal bovine serum
  • Triglyceride Quantification Assay kit was used to measure the pure triglyceride (TG) content in mature adipocytes by treating the lyophilized product of the fermentation product of Example 3.
  • Differentiation-induced pre-adipocytes were homogenized using 5% NP-40 solution, incubated at 90 ° C for 5 minutes, and then reacted at room temperature for 5 minutes to completely dissolve TG. After that, it was reacted with Lipase at room temperature for 20 minutes and reacted with Triglyceride Probe and Triglyceride Enzyme Mix at room temperature for 60 minutes, and the light intensity at 570 nm wavelength was measured with a spectrophotometer.
  • the fermentation product of the present invention was reconstituted at concentrations of 25, 50, and 100 ⁇ g/ml using an aqueous medium (water) and used.
  • Freeze-dried samples of the fermentation product of Example 3 were reconstituted according to Table 7, and after oral administration according to Table 7 to 8-week-old C57BL6J mice with a high-fat diet, body weight changes were measured during the experimental period for 14 weeks.
  • Example 9 The effect of the fermentation product of Example 3 on reducing body fat in the obese animal model induced by the high-fat diet of Experimental Example 9 was measured by Dual energy X-ray Absorptiometry (DXA) to measure the volume of subcutaneous and visceral fat. The results are shown in FIG. 10 .
  • DXA Dual energy X-ray Absorptiometry
  • Example 9 To confirm the effect of the fermentation product of Example 3 on organ weight in the obese animal model induced by the high-fat diet of Experimental Example 9, the weight of liver, epididymis, groin or brown adipose tissue was measured.
  • FIG. 11 Compared to the normal diet group (NCD), the size of epididymal fat increased in the high-fat diet group (HFD) (FIG. 11-A), and compared to the simple high-fat diet group (HFD + vehicle), the liver in the butyrate fermentation product simultaneous administration group of the present invention , the weights of epididymal white fat, inguinal light fat, and brown adipose tissue were lower (FIG. 11-B).
  • the high-dose administration group (BF-1) showed a decrease in tissue weight that was almost similar to or lower than that of the positive control group (SB-0.5).
  • the fermentation product of the present invention according to the examples can inhibit the expression of mast cells, and in the experimental examples, it was confirmed that body weight and body fat mass were reduced. In particular, considering that as the concentration of butyrate increases, it is effective in reducing body weight and fat mass.
  • the butyrate content was about 26 mM
  • the other examples having similar or higher butyrate content were also similar. or will show a more effective weight loss effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un produit de fermentation contenant un acide gras à chaîne courte et son utilisation pour soulager, prévenir ou traiter l'obésité. La présente invention concerne un produit de fermentation contenant un acide gras à chaîne courte, le produit de fermentation comprenant : un extrait de levure comme source d'azote ; au moins un produit choisi dans le groupe constitué par la poudre de soja frit ou la peptone de soja ; et au moins un produit choisi dans le groupe constitué par l'inuline, la poudre de chicorée, la maltodextrine et le glucose comme source de carbone, est produit par inoculation d'une souche de Clostridium dans une composition de milieu ne contenant pas de milieu clostridial renforcé et par fermentation de celui-ci, et contient un acide gras à chaîne courte dans une quantité égale ou supérieure à 10 mM.
PCT/KR2022/017492 2022-02-23 2022-11-08 Produit de fermentation contenant un acide gras à chaîne courte et son utilisation pour soulager, prévenir et traiter l'obésité WO2023163318A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20220023893 2022-02-23
KR10-2022-0023893 2022-02-23
KR10-2022-0148277 2022-11-08
KR1020220148277A KR102660139B1 (ko) 2022-02-23 2022-11-08 단쇄 지방산을 포함하는 발효 생성물 및 그의 과체중 개선, 예방 또는 치료 용도

Publications (1)

Publication Number Publication Date
WO2023163318A1 true WO2023163318A1 (fr) 2023-08-31

Family

ID=87766143

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/017492 WO2023163318A1 (fr) 2022-02-23 2022-11-08 Produit de fermentation contenant un acide gras à chaîne courte et son utilisation pour soulager, prévenir et traiter l'obésité

Country Status (1)

Country Link
WO (1) WO2023163318A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117305381A (zh) * 2023-11-28 2023-12-29 广东容大生物股份有限公司 一种丁酸梭菌在发酵生产丁酸盐中的应用及生产丁酸盐的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07265064A (ja) * 1993-11-23 1995-10-17 Taketoshi Yamada 腸内細菌叢改善組成物
CN1246144A (zh) * 1997-02-14 2000-03-01 日宝化学株式会社 具有预防及治疗肝脏损害功能的丁酸梭菌,以及由其培养物制成的肝保护剂、食品和饲料
US20200345791A1 (en) * 2019-05-01 2020-11-05 The Procter & Gamble Company Probiotic Bacterial Strains That Produce Short Chain Fatty Acids And Compositions Comprising Same
CN112063679A (zh) * 2020-10-09 2020-12-11 山东省大健康精准医疗产业技术研究院 一种混合益生菌发酵复合碳水化合物制备短链脂肪酸的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07265064A (ja) * 1993-11-23 1995-10-17 Taketoshi Yamada 腸内細菌叢改善組成物
CN1246144A (zh) * 1997-02-14 2000-03-01 日宝化学株式会社 具有预防及治疗肝脏损害功能的丁酸梭菌,以及由其培养物制成的肝保护剂、食品和饲料
US20200345791A1 (en) * 2019-05-01 2020-11-05 The Procter & Gamble Company Probiotic Bacterial Strains That Produce Short Chain Fatty Acids And Compositions Comprising Same
CN112063679A (zh) * 2020-10-09 2020-12-11 山东省大健康精准医疗产业技术研究院 一种混合益生菌发酵复合碳水化合物制备短链脂肪酸的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAJARUDIN HUSNUL AZAN BIN: "A study of fatty acid production by Clostridium butyricum", DOCTORAL THESIS, SWANSEA UNIVERSITY, 1 January 2012 (2012-01-01), XP093088129, Retrieved from the Internet <URL:https://core.ac.uk/download/pdf/161880535.pdf> [retrieved on 20231003] *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117305381A (zh) * 2023-11-28 2023-12-29 广东容大生物股份有限公司 一种丁酸梭菌在发酵生产丁酸盐中的应用及生产丁酸盐的方法
CN117305381B (zh) * 2023-11-28 2024-02-02 广东容大生物股份有限公司 一种丁酸梭菌在发酵生产丁酸盐中的应用及生产丁酸盐的方法

Similar Documents

Publication Publication Date Title
WO2017039365A1 (fr) Méthode d&#39;inhibition de l&#39;absorption et/ou de promotion de l&#39;excrétion de lipides à l&#39;aide de d-psicose
WO2019135637A1 (fr) Procédé de préparation d&#39;un extrait de feuille de gynostemma pentaphyllum contenant une quantité accrue de saponine efficace de faible masse moléculaire et une quantité réduite de benzopyrène, et extrait de feuille de gynostemma pentaphyllum préparé selon ledit procédé
WO2010087565A2 (fr) Nouvelle utilisation de la pipérine
WO2023163318A1 (fr) Produit de fermentation contenant un acide gras à chaîne courte et son utilisation pour soulager, prévenir et traiter l&#39;obésité
WO2021261632A1 (fr) Nouvelle souche de faecalibacterium prausnitzii eb-fpdk11 et utilisation associée
WO2011136573A2 (fr) Hydrolysat de levure ayant des effets de traitement de l&#39;obésité et une activité antioxydante
WO2021251575A1 (fr) Nouvelle souche de pediococcus pentosaceus et composition alimentaire pour la prévention ou l&#39;amélioration de l&#39;obésité ou d&#39;une stéatose hépatique comprenant un produit fermenté à base de lactosérum associé
WO2010087577A2 (fr) Utilisation d&#39;extrait de thymus capitatus, d&#39;extrait de satureja hortensis, ou de carvacrol pour traiter des maladies métaboliques
WO2013024950A1 (fr) Composition anti-obésité comprenant un hydrolysat de chrysalides de ver à soie dégraissées et son procédé de préparation
WO2020040382A1 (fr) Nouveau composé de magnésium-sérinate et son utilisation
WO2015111832A1 (fr) Composition de prévention ou de traitement de maladies liées à la prostate, contenant un extrait de poncirus trifoliata
WO2012134172A2 (fr) Composition contenant, comme ingrédient actif, une fraction d&#39;acétate d&#39;éthyle de schisandra chinensis baill, ou wuweizisu c séparée de la fraction, pour prévenir ou traiter l&#39;obésité
WO2018128479A1 (fr) Composition pour la prévention ou le traitement de maladies musculaires, comprenant comme principe actif de l&#39;acide subérique ou un sel pharmaceutiquement acceptable de celui-ci
WO2023120896A1 (fr) Nouvelle souche de lactobacillus plantarum bnt_g401 et utilisation associée
WO2024048934A1 (fr) Nouvelle bactérie lactique lactiplantibacillus plantarum sko-001 pour réduire la graisse corporelle, et ses utilisations
WO2014196775A1 (fr) Souche de lactobacillus brevis g-101 et son utilisation
WO2014189176A1 (fr) Extrait d&#39;ecklonia cava permettant la perte de poids et son procédé de préparation
WO2011074765A2 (fr) Composition incluant un matériel fermenté pour la médecine orientale au titre de principe actif dans le traitement prophylactique et thérapeutique de l&#39;obésité ou de l&#39;hyperlipidémie
WO2010041908A2 (fr) Nouvelle utilisation d&#39;un dérivé de panduratine ou d&#39;un extrait de boesenbergia pandurata
WO2021080298A1 (fr) Composition contenant enterococus faecalis en guise de principe actif pour la prévention ou le traitement de l&#39;obésité ou de syndromes métaboliques induits par cette dernière
WO2021261631A1 (fr) Nouvelle souche de picalibacterium prosnich eb-fpdk9 et utilisations associées
WO2018066969A1 (fr) Composition pharmaceutique comprenant de l&#39;arazyme en tant que principe actif pour la prévention ou le traitement d&#39;une maladie métabolique
WO2017222302A1 (fr) Composition pour améliorer la capacité à l&#39;exercice et traiter l&#39;ostéoporose, contenant un oligosaccharide à base d&#39;acide mannuronique, insaturé et à extrémité non réductrice
WO2013022178A1 (fr) Composition pour prévention et traitement de l&#39;obésité contenant un principe actif sous la forme d&#39;un extrait de préparation végétale mélangée à base de lonicera japonica et d&#39;aurantii nobilis pericarpium fermenté ou non fermenté, et son utilisation
WO2015142098A1 (fr) Composition contenant un extrait de thé fermenté

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22929066

Country of ref document: EP

Kind code of ref document: A1